Omega-3 Supplementation for Smell Dysfunction
NCT02529332 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 110
Last updated 2018-08-21
Summary
Omega-3 supplementation has been shown to have neuroprotective and potentially anti-inflammatory properties in both central and peripheral nerve injuries. The investigators are studying to see if omega-3 supplementation will affect olfactory (smell) function in patients with olfactory dysfunction following endoscopic removal of pituitary tumors.
Conditions
- Sellar/Parasellar Tumor
- Smell Dysfunction
Interventions
- DIETARY_SUPPLEMENT
-
Omega-3
Nature Made Ultra Omega3 Fish Oil 1400mg softgels contains 1000mg of omega 3 per serving. Participants will be instructed to take twice daily for 6 months.
Sponsors & Collaborators
-
Emory University
collaborator OTHER - lead OTHER
Principal Investigators
-
Zara M Patel, MD · Stanford University
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2014-09-30
- Primary Completion
- 2018-04-30
- Completion
- 2018-04-30
Countries
- United States
Study Locations
More Related Trials
-
Effect of Omega-3 Supplements on the Prevention of Cachexia in Head and Neck Cancer Treated With Radio(Chemo)Therapy
NCT01596933 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Omega-3 Fatty Acids in Treating Women With Newly Diagnosed Ductal Carcinoma In Situ and/or Atypical Ductal Hyperplasia
NCT00627276 ·Status: COMPLETED ·Phase: NA
-
Omega-3 Fatty Acids in Treating Patients With Advanced Cancer Who Have Significant Weight Loss
NCT00003077 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Vit D3 and Omega 3 in Chemo Induced Neuropathy
NCT02294149 ·Status: UNKNOWN ·Phase: PHASE3
-
Effects of 12 Weeks of Omega 3 Supplementation on Resting Metabolic Rate
NCT02092649 ·Status: COMPLETED ·Phase: NA
-
Fish Oil and Cardiovascular Suboptimal Health
NCT02103517 ·Status: COMPLETED ·Phase: PHASE3
-
Vitamin D and Omega-3 Inhibit Metabolic Syndrome
NCT01326442 ·Status: COMPLETED ·Phase: PHASE3
-
Omega-3 Fatty Acids and Chemotherapy-induced Neuropathy and Inflammation in Breast Cancer
NCT01049295 ·Status: UNKNOWN ·Phase: PHASE4
-
Omega-3 Fatty Acid in Treating Patients With Stage I-III Breast Cancer
NCT01869764 ·Status: COMPLETED ·Phase: PHASE2
-
Fish Oil and Muscle Function
NCT01308957 ·Status: COMPLETED ·Phase: NA
-
Effects of Fish Oil on the Colon Mucosa
NCT01860352 ·Status: COMPLETED ·Phase: PHASE1
-
Omega-3 Fatty Acids in Preventing Breast Cancer in Women at High Risk of Developing Breast Cancer
NCT00114296 ·Status: UNKNOWN ·Phase: NA
-
Impact of an Optimized Formulation of Omega 3 on the Composition of Atheromatous Plaques in Patients Requiring Carotid Endarterectomy
NCT02582710 ·Status: UNKNOWN ·Phase: PHASE3
-
Fish Oil-derived Omega-3 Fatty Acids on Gut Microbiota and Lipid Metabolome in Type 2 Diabetes Mellitus
NCT06061510 ·Status: COMPLETED ·Phase: NA
-
The Effect of Omega-3 Fatty Acid Supplementation on Intraocular Pressure & Ocular Surface
NCT02295358 ·Status: WITHDRAWN
-
The Effects of Omega-3 Fatty Acids on Metabolic Syndrome
NCT00350194 ·Status: UNKNOWN ·Phase: EARLY_PHASE1
-
Omega-3 to Reduce Diabetes Risk in Subjects With High Number of Particles That Carry "Bad Cholesterol" in the Blood
NCT04496154 ·Status: COMPLETED ·Phase: NA
-
Fish Oil and Alpha Lipoic Acid in Treating Alzheimer's Disease
NCT00090402 ·Status: COMPLETED ·Phase: PHASE1/PHASE2
-
Omega 3 Supplementation and Ocular Surface Disease in Glaucoma
NCT01630551 ·Status: WITHDRAWN ·Phase: NA
-
Deep-sea Fish Oil for Prevention of Acute Radiation-induced Esophagitis
NCT06392971 ·Status: RECRUITING ·Phase: PHASE2
-
Effects of a Prescription Omega-3 Fatty Acid Concentrate on Induced Inflammation
NCT01813110 ·Status: COMPLETED ·Phase: NA
-
Investigating the Effect of 4-week Omega-3 Polyunsaturated Fatty Acid Supplementation on Inflammation
NCT03210805 ·Status: UNKNOWN ·Phase: NA
-
Vascular and Metabolic Effects of Omega-3 Fatty Acids
NCT01660932 ·Status: COMPLETED ·Phase: PHASE4
-
Omega-3-Fatty Acid on Joint Symptoms Inducted by Aromatase Inhibitors
NCT00930527 ·Status: TERMINATED ·Phase: PHASE2
-
n-3 Polyunsaturated Fatty Acids to Prevent and Treat Diabetic Neuropathy
NCT05145452 ·Status: TERMINATED ·Phase: NA